Von Willebrand Disease News and Research

Latest Von Willebrand Disease News and Research

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

Timely treatment with Berinert provides faster symptom relief for HAE patients

Timely treatment with Berinert provides faster symptom relief for HAE patients

Study: Bioavailability similar among four subcutaneous IgG preparations

Study: Bioavailability similar among four subcutaneous IgG preparations

CSL Behring to receive 2012 EURORDIS Award for pioneering work

CSL Behring to receive 2012 EURORDIS Award for pioneering work

Octapharma submits octaplasLG BLA with FDA to treat TTP

Octapharma submits octaplasLG BLA with FDA to treat TTP

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

CSL Behring announces results of rIX-FP Phase I study on hemophilia B

CSL Behring announces results of rIX-FP Phase I study on hemophilia B

Baxter commences BAX 855 Phase I trial in hemophilia A

Baxter commences BAX 855 Phase I trial in hemophilia A

FDA approves CSL Behring's Berinert for treatment of HAE attacks

FDA approves CSL Behring's Berinert for treatment of HAE attacks

Baxter receives FDA approval for ADVATE to prevent hemophilia A

Baxter receives FDA approval for ADVATE to prevent hemophilia A

American Plasma Users Coalition awarded $40,000 advocacy grant from CSL Behring

American Plasma Users Coalition awarded $40,000 advocacy grant from CSL Behring

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

Octapharma receives FDA approval for octagam to treat disorders of immune system

Octapharma receives FDA approval for octagam to treat disorders of immune system

Baxter commences BAX 111 Phase III trial in von Willebrand disease

Baxter commences BAX 111 Phase III trial in von Willebrand disease

New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH

New preclinical data from Baxter's BAX 499 hemophilia study presented at ISTH

Key finding sheds new light on common bleeding disorders

Key finding sheds new light on common bleeding disorders

CSL Behring supports World Federation of Hemophilia with 1 million IUs of von Willebrand factor/Factor VIII

CSL Behring supports World Federation of Hemophilia with 1 million IUs of von Willebrand factor/Factor VIII

European Commission grants Orphan Drug Designation for CSL Behring's rVIIa-FP to treat hemophilia

European Commission grants Orphan Drug Designation for CSL Behring's rVIIa-FP to treat hemophilia

CSL-Behring recombinant factor research presented

CSL-Behring recombinant factor research presented